Skip to main navigation
Skip to search
Skip to main content
The University of Aberdeen Research Portal Home
Help & FAQ
Home
Profiles
Disciplines
Research output
Research Facilities
Datasets
Impacts
Activities
Press/Media
Prizes
Projects
Search by expertise, name or affiliation
Mepolizumab and eosinophil-mediated disease
Garry M. Walsh
Applied Medicine
Research output
:
Contribution to journal
›
Literature review
›
peer-review
29
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Mepolizumab and eosinophil-mediated disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
mepolizumab
100%
Eosinophils
57%
Sputum
29%
Asthma
23%
Interleukin-5
22%
Eosinophilia
21%
Hypereosinophilic Syndrome
14%
Eosinophilic Esophagitis
14%
Antibodies, Monoclonal, Humanized
12%
Prednisone
10%
Therapeutics
9%
Allergens
9%
Gastrointestinal Tract
8%
Bone Marrow
7%
Clinical Trials
6%
Quality of Life
6%
Pathology
6%
Skin
5%
Chemical Compounds
Prednisone
92%
Allergen
74%
Refractory
62%
Reduction
27%